All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.

More information on our cookie policy.

BioWorld. Link to homepage.

/images/Cortellis_Flagship_Logo_TM_RGB_Color.png
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
  • Special reports
    • Artificial intelligence
    • Coronavirus
    • Diagnosing and tracking COVID-19
    • Drugs to Watch 2020
    • The next pandemic
    • Premium reports
      • BioWorld Financings Reports
      • Disease Forecast Reports

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Wednesday, March 3, 2021
Home » Blogs » BioWorld MedTech Perspectives » The Supreme Court speaks: Is the Myriad story over?

BioWorld MedTech Perspectives
BioWorld MedTech Perspectives RSS FeedRSS

BioWorld MedTech

The Supreme Court speaks: Is the Myriad story over?

June 19, 2013
By Mark McCarty
No Comments

Watson & Crick, a couple of real troublemakers
Watson & Crick; a couple of real troublemakers

The Supreme Court finally published its decision in the case of Association for Molecular Pathology v. Myriad Genetics, a case that seemed to hover over the landscape of life science patents for an eternity. We might be tempted to think the decision shuts the door on a very contentious area of patent law. After all, we now know isolated DNA is not patentable, but complementary DNA is. So that’s it, right?

Wrong. In fact, at least one observer believes the decision may collapse at some point.

Richard Gilly with the law firm of Akerman (Washington) told me in an interview “there will be some challenges to existing patents” because of the ruling, but he also noted that the proteins used in proteomics might be next up for this kind of scrutiny. Jim Crowne, director of legal affairs at the American Intellectual Property Law Association in Arlington, Virginia, also chimed in for the coverage at Medical Device Daily, stating that the ruling is something of a 40,000-foot document. Crowne said, “the main question [going forward] is how marked the difference is between what occurs naturally and what you have described in your application.”

The range of opinions doesn’t stop there, however. In an entry at the blog at patentlyo.com, Dennis Crouch writes that John Duffy, a professor of law at the University of Virginia, described the outcome as “a half-loss to inventors, a half-loss to advocates for a broader public domain but, unfortunately, a full victory for patent lawyers, who will have lots of business opining on and litigating the complexities of this decision.”

In other words, it’s nowhere near over if this decision is going to keep the patent bar busy.

Crouch’s posting at patentlyo indicates that Brenda Simon of the Thomas Jefferson School of Law said Myriad “does not impact one of the most valuable aspects made possible through Myriad's patent protection: a private biobank of patient data containing information about additional mutations that Myriad can maintain as a trade secret.”

I would point out that Simon’s remarks echo a lot of comments I’ve heard about the Myriad patent. Interested parties I’ve talked to off the record have asserted the real value of the patent for the BRCA 1 and 2 genes is not for use as a diagnostic, but for development of therapeutics for treatment of BRCA-related breast cancer.

But one of the most interesting comments I’ve seen on this was offered by Andrew Chin of the University of North Carolina School of Law, who said the decision means that patents on DNA probes “are problematic” where the section 101 test (subject matter eligibility) is concerned. Chin said the problem extends to DNA research “regardless of whether the probes are produced by isolation or synthesis,” adding that the distinction “will distort scientific and medical progress and ultimately prove to be doctrinally unstable.”

So, patent geeks and wonks, there’s no need to despair. The SCOTUS decision merely closed chapter one of the Myriad story. Chapter two is just beginning.

You must login or register in order to post a comment.

Report Abusive Comment

Popular Stories

  • Free access to BioWorld coronavirus articles

    BioWorld

    The articles in this collection are from BioWorld’s ongoing coverage of the COVID-19 coronavirus outbreak. Note that we have added three critical tables which are...

  • Today's news in brief

    BioWorld
    BioWorld briefs for March 2.
  • Gloved hand places sample tubes in PCR system

    COVID-19 test makers are adapting for variants

    BioWorld MedTech
    As COVID-19 variants have emerged, so have questions about the effectiveness of tests for infection. While the risk of mutations significantly limiting their...
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech's briefs for March 2.
  • Celltrion-Regkirona-2-9

    Celltrion wins first conditional Korean approval for COVID-19 antibody Regkirona

    BioWorld
    HONG KONG – Celltrion Inc. has received conditional marketing authorization from the Ministry of Food and Drug Safety (MFDS) for its anti-COVID-19 monoclonal...
cortellis ad

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Subscribe
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • About
    • Archives
    • Today's news
    • Search BioWorld Science
  • More
    • About
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
A Clarivate Analytic solution. Link to Clarivate website.
Follow Us

Copyright ©2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing